Medication info
Telostop Tablet 40/10 Milligrams

Telostop Tablet 40/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Bright blue oval-shaped film-coated tablets
Packaging
30 tablets/box[(10 tablets/Alu-Alu)x3], 30 tablets/bottle
Approval status
Active

MFDS item code 201504095 · Approved 2015.06.23 · Insurance code 642905480

Summary

Main use
Treatment of hypertension and dyslipidemia, reduction of cardiovascular risk, and inhibition of the progression of atherosclerosis
Who takes it
Adults
Adult dose
This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This drug provides additional blood pressure-lowering effects when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this drug is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When initiating treatment with this drug to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this drug, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this drug at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this drug is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, reduction of cardiovascular risk, and inhibition of the progression of atherosclerosis

  • Essential hypertension
  • hypercholesterolemia
  • familial hypercholesterolemia
  • mixed dyslipidemia
  • abnormal beta-lipoproteinemia
View approved original text

This medication is used for patients who need to take telmisartan and rosuvastatin simultaneously. Telmisartan is effective for treating essential hypertension and reducing the risk of cardiovascular disease, particularly helping to lower the risks of myocardial infarction, stroke, and death in high-risk cardiovascular disease patients. Rosuvastatin is used for the treatment of various dyslipidemias, including primary hypercholesterolemia and mixed dyslipidemia, and helps to lower total cholesterol and LDL cholesterol to target levels, slowing the progression of atherosclerosis when combined with dietary therapy. Additionally, it helps reduce the risks of stroke, myocardial infarction, and endovascular procedures in patients with high cardiovascular disease risk. Thus, these two components are used to improve cardiovascular health by managing both hypertension and hyperlipidemia simultaneously.

How to take

Adult dose

This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This drug provides additional blood pressure-lowering effects when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this drug is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When initiating treatment with this drug to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this drug, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this drug at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this drug is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus during pregnancy, so if pregnancy is confirmed, it should be immediately discontinued. Those allergic to this medication or its components should not take it. Pregnant women or those who may become pregnant, as well as nursing mothers, should not take this medication, and women of childbearing potential should use appropriate contraception. Patients with severely impaired liver function or problems with bile excretion should avoid using this medication. Individuals with a history of muscle disorders or hereditary angioedema, as well as patients with severe renal impairment, should also refrain from taking it. If taking with certain immunosuppressants, or in patients with diabetes and moderate or severe renal impairment, avoid using some components of this medication. Patients with genetic issues such as lactose intolerance should not take this medication. Elderly patients, those with elevated potassium levels, and patients with mild to moderate liver dysfunction should take this medication cautiously. Patients with a history of liver disease or those who consume alcohol excessively should regularly undergo liver function tests. Patients with heart disease or vascular disease, or gastrointestinal conditions should exercise caution. Patients with renal artery stenosis, severe renal impairment, or myasthenia gravis should also take care when using it. This medication may increase the risk of muscle-related side effects when used with other antihypertensives or lipid-lowering agents, so caution is advised. If symptoms such as muscle pain or weakness arise, consult a doctor immediately, and if needed, perform blood tests to check for muscle damage. This medication can cause liver dysfunction, requiring regular liver function tests. Since blood pressure may drop too low, notify healthcare personnel immediately if symptoms of hypotension appear. Dizziness or drowsiness may occur while driving or operating machinery during the use of this medication, so caution is necessary. In the event of overdose, there may be hypotension, dizziness, acute renal failure, and one should seek proper treatment at a hospital immediately. This medication is not recommended for children as safety and efficacy have not been established.

Side effects

Headache, position-related dizziness, sleep paralysis, elevated blood pressure, decreased blood pressure, hypotension, elevated ALT, painful urination, rhinitis, discomfort in the oropharynx, lung disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, liver damage, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, hypoglycemia, angioedema, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbance, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe muscular weakness, ocular myasthenia, hypotension, tachycardia, bradycardia, dizziness, acute renal failure, hypotension, shock, loss of consciousness, liver dysfunction, jaundice, anaphylaxis-like symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, insufficient effect, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, thrombocytopenia, increased serum creatinine, joint pain, fatigue, numbness, discomfort in the chest, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air or moisture from entering, and it is important to maintain a storage temperature between 1 to 30 degrees Celsius to preserve its effectiveness for a long time.

Appearance and packaging

Appearance

Bright blue oval-shaped film-coated tablets

Package unit

30 tablets/box[(10 tablets/Alu-Alu)x3], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.